Pathological findings directing immunotherapy in renal cell carcinomas.

Immunotherapy PD-1 PD-L1 nivolumab renal cell carcinoma

Journal

Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158

Informations de publication

Date de publication:
12 Jan 2024
Historique:
medline: 12 1 2024
pubmed: 12 1 2024
entrez: 12 1 2024
Statut: aheadofprint

Résumé

Tweetable abstract Immunotherapy options in RCC treatment are increasing day by day. In pursuit of this objective, we have explored the role of pathology throughout the process, from the development to the implementation of immunotherapy in this paper.

Identifiants

pubmed: 38214137
doi: 10.2217/imt-2023-0249
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Fadime Eda Gökalp Satıcı (FE)

Department of pathology, Tarsus State Hospital, Mersin, 33460, Turkey.

Yasemin Yuyucu Karabulut (YY)

Department of pathology, Mersin University, Mersin, 33100, Turkey.

Classifications MeSH